BIM bioMérieux S.A.

100.36USD91.30 EUR · EPA+0.16%Mkt Cap: 11.84B USDP/E: 23.41

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It ope…

Institutional holders11 on file

Key Statistics

Company
Market Cap11.84B USD
Enterprise Value11.55B USD
Revenue (TTM)4.39B USD
Gross Profit2.54B USD
Net Income (TTM)436.93M USD
Revenue/Share37.27 USD
Last Price100.36 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14.6K
CountryFR
SectorHealthcare
IndustryDiagnostics & Research
ISINFR0013280286
Valuation
P/E (Trailing)23.41
P/E (Forward)19.48
PEG2.11
EV/EBITDA10.01
EV/Revenue2.63
P/S2.70
P/B2.50
EPS (TTM)4.29 USD
EPS (Forward)5.15 USD
52W Range
72.1151% of range127.62
52W High127.62 USD
52W Low72.11 USD
Profitability
Gross Margin56.73%
Oper. Margin16.03%
EBITDA Margin26.33%
Profit Margin9.77%
ROE9.69%
ROA7.13%
ROIC13.12%
ROCE15.40%
Growth
Revenue Growth-3.90%
Earnings Growth41.90%
Cash Flow & Leverage
Operating CF866.61M USD
CapEx (TTM)368.56M USD
FCF Margin14.77%
FCF Yield5.47%
Net Debt-259.30M USD
Net Debt/EBITDA-0.22
Net Debt/FCF-0.40
Balance Sheet
Debt/Equity0.11
Current Ratio2.30
Quick Ratio1.44
Book Value/Sh40.13 USD
Cash/Share6.14 USD
Dividends
Fwd Div Rate1.08 USD
Trail. Div Rate1.08 USD
Div. Yield1.08%
5Y Avg Yield0.84%
Payout Ratio25.13%
Ex-Div DateJun 9, 2026
Pay Date—
Splits
Last Split3:1
Split DateSep 20, 2017
Analyst Consensus
Rating2.8 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)97.87 USD
Upside (mean)-2.5%
Target Range82.44 USD – 116.52 USD
82.44-2.5% to mean116.52
# Analysts13
Ownership
Shares Out.117.95M
Float40.02M
Insiders66.46%
Institutions15.17%
Technical
SMA 5092.18 (+8.9%)
SMA 20088.18 (+13.8%)
Beta0.59
S&P 52W Chg8.68%
Avg Vol (30d)157.63K
Avg Vol (10d)136.07K
Technical Indicators
RSI (14)56.2
MACD1.6913
MACD Signal2.4100
MACD Hist.-0.7188
BB Upper105.53 USD
BB Middle100.98 USD
BB Lower96.43 USD
BB Width9.01%
ATR (14)2.115 USD
Vol Ratio (20d)1.23x

About bioMérieux (EPA: BIM)

›

bioMérieux (EPA: BIM) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 14,562 employees.

The shares were at 91.30 EUR on 20 November 2026, down 16.0% over 52 weeks. Its 52-week range is 65.60 EUR to 116.10 EUR: the price is 21.4% below the high and 39.2% above the low.

At a market capitalisation of 10.77B EUR, it trades at 23.4 times trailing earnings and 19.5 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.6, a discount of 32% for BIM. It pays a dividend yielding 1.08% (it pays out 25% of its earnings), against a median of 0.73% among the dividend payers in that peer group.

bioMérieux reports return on equity of 9.7%, an operating margin of 16.0% and revenue down 3.9% year over year.

It holds more cash than debt, a net cash position of 235.90M EUR. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Hold; their mean price target of 89.04 EUR is 2.5% below the current price. The next earnings report is expected on 25 February 2027.